Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Asthma Market Outlook

Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Asthma Overview

Asthma represents a multifaceted clinical syndrome characterized by variable airflow obstruction, bronchial hyperresponsiveness (BHR), and cellular inflammation. The Global Initiative for Asthma (GINA) defines asthma as a heterogeneous disease primarily marked by airway inflammation. The presence of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, exhibiting variability over time and in intensity, alongside variable expiratory airflow limitation, constitutes the defining features of asthma. This condition results in fluctuating respiratory symptoms and variable airflow limitation, culminating in compromised activity levels, diminished quality of life, and occasional exacerbations, colloquially termed 'asthma attacks.' These exacerbations may necessitate emergency healthcare utilization and hospitalization and, in rare instances, lead to fatalities. Asthma's risk factors encompass genetic, environmental, and host-related elements. While a family history of asthma is common, it is neither sufficient nor necessary for asthma development. Clinical categorization of asthma involves classifying it as mild intermittent, mild persistent, moderate persistent, or severe persistent based on symptom frequency, severity, and lung function assessed through forced expiratory volume in 1 second (FEV1). Asthma manifests in various types, including allergic asthma, aspirin-induced asthma, cough-variant asthma, exercise-induced asthma, nighttime asthma, steroid-resistant asthma, and occupational asthma. Asthma is frequently associated with comorbidities that can impact its clinical expression, with rhinitis, sinusitis, gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), hormonal disorders, and psychopathologies reported as common contributing conditions. Although the specific influence of these comorbidities is yet to be fully characterized, their presence is noteworthy. Additionally, other conditions, sometimes unrelated to asthma, exhibit high prevalence among asthmatic patients. The pharmacological management of asthma involves several major drug classes, including bronchodilators (beta-2 agonists, anticholinergics), corticosteroids, leukotriene modifiers, mast cell stabilizers, methylxanthines, and immunomodulators. These drugs can be administered through inhalation, oral ingestion, or subcutaneous and intravenous injection, with inhaled forms available in aerosolized and powdered formulations.

• In the United States, over 27 million individuals are affected by asthma, with a higher prevalence among male children compared to their female counterparts. Approximately 7% of male children and 5.4% of female children experience asthma.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: